Models and discovery strategies for new therapies of retinoblastoma

Bibliography

• Khidr L, Chen PL. RB, the conductor that orchestrates life, death and differentiation. Oncogene 2006;25:5210-19
   PubMed Web of Science ®Google Scholar
• Mastrangelo D, De Francesco S, Di Leonardo A, Does the evidence matter in medicine? The retinoblastoma paradigm. Int J Cancer 2007;121:2501-5
   PubMed Web of Science ®Google Scholar
• Reid TW, Albert DM, Rabson AS, Characteristics of an established cell line of retinoblastoma. J Natl Cancer Inst 1974;53:347-60
   PubMed Web of Science ®Google Scholar
• McFall RC, Sery TW, Makadon M. Characterization of a new continuous cell line derived from a human retinoblastoma. Cancer Res 1977;37:1003-10
   PubMed Web of Science ®Google Scholar
• Howard MA, Wardwell S, Albert DM. Effect of butyrate and corticosteroids on retinoblastoma in vitro and in vivo. Invest Ophthalmol Vis Sci 1991;32:1711-13
   PubMed Web of Science ®Google Scholar
• White L, Reed C, Tobias V. Comparison of cyclophosphamide and diaziquone in a retinoblastoma xenograft model. Ophthalmic Paediatr Genet 1989;10:99-105
   PubMed Web of Science ®Google Scholar
• Madreperla SA, Whittum-Hudson JA, Prendergast RA, Intraocular tumor suppression of retinoblastoma gene-reconstituted retinoblastoma cells. Cancer Res 1991;51:6381-4
   PubMed Web of Science ®Google Scholar
• Chevez-Barrios P, Hurwitz MY, Louie K, Metastatic and nonmetastatic models of retinoblastoma. Am J Pathol 2000;157:1405-12
   PubMed Web of Science ®Google Scholar
• O'Brien JM, Marcus DM, Niffenegger AS, Trilateral retinoblastoma in transgenic mice. Trans Am Ophthalmol Soc 1989;87:301-22; discussion 322-306
   PubMedGoogle Scholar
• Zhang J, Schweers B, Dyer MA. The first knockout mouse model of retinoblastoma. Cell Cycle 2004;3:952-9
   PubMed Web of Science ®Google Scholar
• Friend SH, Bernards R, Rogelj S, A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986;323:643-6
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Khare S, Dorairaj SK, Identification of genes associated with tumorigenesis of retinoblastoma by microarray analysis. Genomics 2007;90:344-53
   PubMed Web of Science ®Google Scholar
• Ganguly A, Shields CL. Differential gene expression profile of retinoblastoma compared to normal retina. Mol Vis 2010;16:1292-303
   PubMed Web of Science ®Google Scholar
• Houston SK, Pina Y, Clarke J, Regional and temporal differences in Gene expression of LHBETATAG retinoblastoma tumors. Invest Ophthalmol Vis Sci 2011;52(8):5359-68
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
   PubMed Web of Science ®Google Scholar
• Konerding MA, Miodonski AJ, Lametschwandtner A. Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc 1995;9:1233-43; discussion 1243-1234
   PubMedGoogle Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10
   PubMed Web of Science ®Google Scholar
• Jockovich ME, Bajenaru ML, Pina Y, Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model. Invest Ophthalmol Vis Sci 2007;48:2476-82
   PubMed Web of Science ®Google Scholar
• Pina Y, Cebulla CM, Murray TG, Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculature. Ophthalmic Res 2009;41:160-9
   PubMed Web of Science ®Google Scholar
• Pina Y, Boutrid H, Schefler A, Blood vessel maturation in retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment. Invest Ophthalmol Vis Sci 2009;50:1020-4
   PubMed Web of Science ®Google Scholar
• Griggs J, Skepper JN, Smith GA, Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Am J Pathol 2002;160:1097-103
   PubMed Web of Science ®Google Scholar
• Clark AF. AL-3789: a novel ophthalmic angiostatic steroid. Expert Opin Investig Drugs 1997;6:1867-77
   PubMedGoogle Scholar
• Bajenaru ML, Pina Y, Murray TG, Gelatinase expression in retinoblastoma: modulation of LH(BETA)T(AG) retinal tumor development by anecortave acetate. Invest Ophthalmol Vis Sci 2010;51:2860-4
   PubMed Web of Science ®Google Scholar
• Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9-34
   PubMed Web of Science ®Google Scholar
• Adithi M, Nalini V, Kandalam M, Krishnakumar S. Expression of matrix metalloproteinases and their inhibitors in retinoblastoma. J Pediatr Hematol Oncol 2007;29:399-405
   PubMed Web of Science ®Google Scholar
• Escalona-Benz E, Jockovich ME, Murray TG, Combretastatin A-4 prodrug in the treatment of a murine model of retinoblastoma. Invest Ophthalmol Vis Sci 2005;46:8-11
   PubMed Web of Science ®Google Scholar
• Jockovich ME, Murray TG, Escalona-Benz E, Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice. Invest Ophthalmol Vis Sci 2006;47:1264-8
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009;27:2278-87
   PubMed Web of Science ®Google Scholar
• Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008;8:851-64
   PubMed Web of Science ®Google Scholar
• Pina Y, Decatur C, Murray T, Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors. Clin Ophthalmol 2011;5:337-43
   PubMedGoogle Scholar
• Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008;8:425-37
   PubMed Web of Science ®Google Scholar
• Boutrid H, Jockovich ME, Murray TG, Targeting hypoxia, a novel treatment for advanced retinoblastoma. Invest Ophthalmol Vis Sci 2008;49:2799-805
   PubMedGoogle Scholar
• Pina Y, Houston SK, Murray TG, Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma. Invest Ophthalmol Vis Sci 2010;51:6149-56
   PubMed Web of Science ®Google Scholar
• Pina Y, Decatur C, Murray TG, Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors. Invest Ophthalmol Vis Sci 53:996-1002
   PubMed Web of Science ®Google Scholar
• Ma J, Pulfer S, Li S, Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res 2001;61:5491-8
   PubMed Web of Science ®Google Scholar
• Houston SK, Pina Y, Murray TG, Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors. Clin Ophthalmol 2011;5:129-37
   PubMedGoogle Scholar
• Su RY, Chao Y, Chen TY, 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNF{alpha}-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling. Mol Cancer Ther 2007;6:1562-71
   PubMed Web of Science ®Google Scholar
• Rattan R, Giri S, Singh AK, Singh I. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 2005;280:39582-93
   PubMed Web of Science ®Google Scholar
• Baumann P, Mandl-Weber S, Emmerich B, Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells. Exp Cell Res 2007;313:3592-603
   PubMed Web of Science ®Google Scholar
• Guo D, Hildebrandt IJ, Prins RM, The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci USA 2009;106:12932-7
   PubMed Web of Science ®Google Scholar
• Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer. 2007;6:46
   Google Scholar
• Theodoropoulou S, Kolovou PE, Morizane Y, Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase. FASEB J 2010;24:2620-30
   PubMed Web of Science ®Google Scholar
• Laurie NA, Donovan SL, Shih CS, Inactivation of the p53 pathway in retinoblastoma. Nature 2006;444:61-6
   PubMed Web of Science ®Google Scholar
• Elison JR, Cobrinik D, Claros N, Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. Arch Ophthalmol 2006;124:1269-75
   PubMed Web of Science ®Google Scholar
• Laurie NA, Gray JK, Zhang J, Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res 2005;11:7569-78
   PubMed Web of Science ®Google Scholar
• Brennan RC, Federico S, Bradley C, Targeting the p53 Pathway in Retinoblastoma with Subconjunctival Nutlin-3a. Cancer Res 2011;71:4205-13
   PubMed Web of Science ®Google Scholar
• McCormick B, Ellsworth R, Abramson D, Radiation therapy for retinoblastoma: comparison of results with lens-sparing versus lateral beam techniques. Int J Radiat Oncol Biol Phys 1988;15:567-74
   PubMed Web of Science ®Google Scholar
• Murray TG, O'Brien JM, Steeves RA, Radiation therapy and ferromagnetic hyperthermia in the treatment of murine transgenic retinoblastoma. Arch Ophthalmol 1996;114:1376-81
   PubMed Web of Science ®Google Scholar
• Hayden BC, Murray TG, Cicciarelli N, Hyperfractionated external beam radiation therapy in the treatment of murine transgenic retinoblastoma. Arch Ophthalmol 2002;120:353-9
   PubMed Web of Science ®Google Scholar
• Sobrin L, Hayden BC, Murray TG, External beam radiation “salvage” therapy in transgenic murine retinoblastoma. Arch Ophthalmol 2004;122:251-7
   PubMed Web of Science ®Google Scholar
• Reisner ML, Viegas CM, Grazziotin RZ, Retinoblastoma–comparative analysis of external radiotherapy techniques, including an IMRT technique. Int J Radiat Oncol Biol Phys 2007;67:933-41
   PubMed Web of Science ®Google Scholar
• Krengli M, Hug EB, Adams JA, Proton radiation therapy for retinoblastoma: comparison of various intraocular tumor locations and beam arrangements. Int J Radiat Oncol Biol Phys 2005;61:583-93
   PubMed Web of Science ®Google Scholar
• Lee CT, Bilton SD, Famiglietti RM, Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys 2005;63:362-72
   PubMed Web of Science ®Google Scholar
• Lane AM, Kim IK, Gragoudas ES. Proton irradiation for peripapillary and parapapillary melanomas. Arch Ophthalmol 2012;129:1127-30
   Web of Science ®Google Scholar
• Prasanna VK, Venkataramana NK, Dwarakanath BS, Santhosh V. Differential responses of tumors and normal brain to the combined treatment of 2-DG and radiation in glioablastoma. J Cancer Res Ther 2009;5(Suppl 1):S44-7
   PubMed Web of Science ®Google Scholar
• Sugimachi K, Kitamura K, Baba K, Hyperthermia combined with chemotherapy and irradiation for patients with carcinoma of the oesophagus–a prospective randomized trial. Int J Hyperthermia 1992;8:289-95
   PubMed Web of Science ®Google Scholar
• Pfeffer MR, Teicher BA, Holden SA, The interaction of cisplatin plus etoposide with radiation +/- hyperthermia. Int J Radiat Oncol Biol Phys 1990;19:1439-47
   PubMed Web of Science ®Google Scholar
• Ohno S, Siddik ZH, Baba H, Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Res 1991;51:2994-3000
   PubMed Web of Science ®Google Scholar
• Di Filippo F, Carlini S, Garinei R, Local hyperthermia and systemic chemotherapy for treatment of recurrent melanoma. World J Surg 1995;19:359-62
   PubMed Web of Science ®Google Scholar
• Murphree AL, Villablanca JG, Deegan WF III, Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1348-56
   PubMed Web of Science ®Google Scholar
• Gallie BL, Budning A, DeBoer G, Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996;114:1321-8
   PubMed Web of Science ®Google Scholar
• Murray TG, Cicciarelli N, McCabe CM, In vitro efficacy of carboplatin and hyperthermia in a murine retinoblastoma cell line. Invest Ophthalmol Vis Sci 1997;38:2516-22
   PubMed Web of Science ®Google Scholar
• Rodriguez-Galindo C, Wilson MW, Haik BG, Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 2003;21:2019-25
   PubMed Web of Science ®Google Scholar
• Gombos DS, Kelly A, Coen PG, Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age. Br J Ophthalmol 2002;86:80-3
   PubMed Web of Science ®Google Scholar
• Schefler AC, Cicciarelli N, Feuer W, Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology 2007;114:162-9
   PubMed Web of Science ®Google Scholar
• Shields CL, Mashayekhi A, Au AK, The International classification of retinoblastoma predicts chemoreduction success. Ophthalmology 2006;113:2276-80
   PubMed Web of Science ®Google Scholar
• Shields CL, Shields JA. Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol 2006;17:228-34
   PubMed Web of Science ®Google Scholar
• Turaka K, Shields CL, Meadows AT, Leahey A. Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer 2012;59(1):121-5
   PubMed Web of Science ®Google Scholar
• Gombos DS, Hungerford J, Abramson DH, Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology 2007;114:1378-83
   PubMed Web of Science ®Google Scholar
• Jehanne M, Lumbroso-Le Rouic L, Savignoni A, Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer 2009;52:637-43
   PubMed Web of Science ®Google Scholar
• Smits C, Swen SJ, Theo Goverts S, Assessment of hearing in very young children receiving carboplatin for retinoblastoma. Eur J Cancer 2006;42:492-500
   PubMed Web of Science ®Google Scholar
• Lambert MP, Shields C, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer 2008;50:223-6
   PubMed Web of Science ®Google Scholar
• Jehanne M, Mercier G, Doz F. Monitoring of ototoxicity in young children receiving carboplatin for retinoblastoma. Pediatr Blood Cancer 2009;53:1162
   Google Scholar
• Leahey A. A cautionary tale: dosing chemotherapy in infants with retinoblastoma. J Clin Oncol 2012;30:1023-4
   PubMed Web of Science ®Google Scholar
• Harbour JW, Murray TG, Hamasaki D, Local carboplatin therapy in. transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 1996;37:1892-8
   PubMed Web of Science ®Google Scholar
• Murray TG, Roth DB, O'Brien JM, Local carboplatin and radiation therapy in the treatment of murine transgenic retinoblastoma. Arch Ophthalmol 1996;114:1385-9
   PubMed Web of Science ®Google Scholar
• Ueda M, Tanabe J, Inomata M, Kaneko A. Kimura T. [Study on conservative treatment of retinoblastoma–effect of intravitreal injection of melphalan on the rabbit retina]. Nihon Ganka Gakkai Zasshi 1995;99:1230-5
   PubMedGoogle Scholar
• Munier FL, Soliman S, Moulin AP, Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track. Br J Ophthalmol 2012;96:1084-7
   PubMed Web of Science ®Google Scholar
• Munier FL, Gaillard MC, Balmer A, Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol 2012;96:1078-83
   PubMed Web of Science ®Google Scholar
• Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol 2012;130:1268-71
   PubMed Web of Science ®Google Scholar
• Murray TG, Cicciarelli N, O'Brien JM, Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma. Arch Ophthalmol 1997;115:1286-90
   PubMed Web of Science ®Google Scholar
• Mendelsohn ME, Abramson DH, Madden T, Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol 1998;116:1209-12
   PubMed Web of Science ®Google Scholar
• Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 1999;106:1947-50
   PubMed Web of Science ®Google Scholar
• Kim JW, Yau JW, Moshfeghi D, Fishman M. Orbital fibrosis and intraocular recurrence of retinoblastoma following periocular Carboplatin. J Pediatr Ophthalmol Strabismus 2010;47:e1-4
   Google Scholar
• Schmack I, Hubbard GB, Kang SJ, Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol 2006;142:310-15
   PubMed Web of Science ®Google Scholar
• Pina Y, Boutrid H, Murray TG, Ophthalmic vasculature alterations following systemic chemotherapy and periocular Carboplatin treatment of advanced retinoblastoma. J Pediatr Ophthalmol Strabismus 2010;47:e1-5
   PubMedGoogle Scholar
• Marr BP, Dunkel IJ, Linker A, Abramson DH. Periocular carboplatin for retinoblastoma: long-term report (12 years) on efficacy and toxicity. Br J Ophthalmol 2012;96:881-3
   PubMed Web of Science ®Google Scholar
• Van Quill KR, Dioguardi PK, Tong CT, Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology 2005;112:1151-8
   PubMed Web of Science ®Google Scholar
• Hayden BC, Jockovich ME, Murray TG, Pharmacokinetics of systemic versus focal Carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma. Invest Ophthalmol Vis Sci 2004;45:3644-9
   PubMed Web of Science ®Google Scholar
• Hayden B, Jockovich ME, Murray TG, Iontophoretic delivery of carboplatin in a murine model of retinoblastoma. Invest Ophthalmol Vis Sci 2006;47:3717-21
   PubMed Web of Science ®Google Scholar
• Reese AB, Hyman GA, Merriam GR Jr, Treatment of retinoblastoma by radiation and triethylenemelamine. AMA Arch Ophthalmol 1954;53:505-13
   PubMed Web of Science ®Google Scholar
• Mohri M. The development of a new system of selective ophthalmic arterial infusion for the patients of intraocular retinoblastoma (in Japanese). Keio Igaku (J Keio Med Soc) 1993;70:679-87
   Google Scholar
• Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 2004;9:69-73
   PubMedGoogle Scholar
• Abramson DH, Dunkel IJ, Brodie SE, A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 2008;115:1398-404; 1404 e1391
   PubMed Web of Science ®Google Scholar
• Abramson DH, Dunkel IJ, Brodie SE, Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology 2010;117:1623-9
   PubMed Web of Science ®Google Scholar
• Gobin YP, Dunkel IJ, Marr BP, Intra-arterial Chemotherapy for the Management of Retinoblastoma: four-Year Experience. Arch Ophthalmol 2011;129(6):732-7
   PubMed Web of Science ®Google Scholar
• Vajzovic LM, Murray TG, Aziz-Sultan MA, Supraselective intra-arterial chemotherapy: evaluation of treatment-related complications in advanced retinoblastoma. Clin Ophthalmol 2011;5:171-6
   PubMedGoogle Scholar
• Peterson EC, Elhammady MS, Quintero-Wolfe S, Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors. J Neurosurg 2011;114(6):1603-8
   PubMed Web of Science ®Google Scholar
• Vajzovic LM, Murray TG, Aziz-Sultan MA, Clinicopathologic review of enucleated eyes after intra-arterial chemotherapy with melphalan for advanced retinoblastoma. Arch Ophthalmol 2010;128:1619-23
   PubMed Web of Science ®Google Scholar
• Shields CL, Bianciotto CG, Jabbour P, Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol 2011;129:1399-406
   PubMed Web of Science ®Google Scholar